Sandoz Group AG (LON:0SAN)
London · Delayed Price · Currency is GBP · Price in CHF | Market Cap | 27.31B +111.7% |
| Revenue (ttm) | 8.29B +7.4% |
| Net Income | 679.10M |
| EPS | 1.55 |
| Shares Out | n/a |
| PE Ratio | 40.22 |
| Forward PE | 20.80 |
| Dividend | 0.75 (1.19%) |
| Ex-Dividend Date | Apr 13, 2026 |
| Volume | 48,041 |
| Average Volume | 179,785 |
| Open | 66.30 |
| Previous Close | 66.72 |
| Day's Range | 66.12 - 67.54 |
| 52-Week Range | 36.20 - 72.69 |
| Beta | 0.61 |
| RSI | 58.82 |
| Earnings Date | Aug 5, 2026 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
News
Sandoz CEO Says Size of Weight-Loss Generics Market Is Unknown
Switzerland's Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.
Sandoz upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded Sandoz (SDZNY) to Overweight from Equal Weight with an unchanged price target of CHF 75. The firm finds the stock’s valuation “compelling” given Sandoz’s accelerating sales growth th...
Sandoz price target lowered to CHF 65 from CHF 70 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Sandoz (SDZNY) to CHF 65 from CHF 70 and keeps a Hold rating on the shares.
Sandoz price target raised to CHF 75 from CHF 66 at JPMorgan
JPMorgan analyst Sophia Graeff Buhl Nielsen raised the firm’s price target on Sandoz (SDZNY) to CHF 75 from CHF 66 and keeps an Overweight rating on the shares. Published first
Sandoz initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of Sandoz (SDZNY) with a Buy rating and CHF 74 price target The firm views Sandoz as a global leader in the generics and biosimilar industry.
Sandoz downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Natalia Webster downgraded Sandoz (SDZNY) to Sector Perform from Outperform with a price target of CHF 65, up from CHF 53. The firm cites valuation for the
Sandoz announces partnership agreement with Samsung Bioepis
Sandoz (SDZNY) announced a major license, development and commercialization partnership agreement with Samsung Bioepis. The agreement paves the way for the two companies to partner on up to five biosi...
Sandoz price target raised to CHF 62 from CHF 55 at Berenberg
Berenberg raised the firm’s price target on Sandoz (SDZNY) to CHF 62 from CHF 55 and keeps a Hold rating on the shares.
Sandoz downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded Sandoz (SDZNY) to Hold from Buy with a CHF 70 price target
Sandoz downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Sandoz (SDZNY) to Equal Weight from Overweight with a price target of CHF 75, up from CHF 70. The firm cites valuation for the downgrade with the shares
Sandoz Shares Jump on Improved Guidance
Stock rose 6.4% after the company bumped up its revenue guidance thanks to growth in its biosimilar product range.
Sandoz confirms E.C. granted marketing authorization for Ranluspec
Sandoz (SDZNY) confirmed that the European Commission, E.C., has granted marketing authorization for Ranluspec. Ranluspec is developed, manufactured and registered by Lupin and was approved based on t...
Sandoz receives U.S. FDA approval to expand Enzeevu label
Sandoz (SDZNY) announced that the US Food and Drug Administration, FDA, has approved an expanded label for Enzeevu, to include multiple retinal indications. Enzeevu was originally approved by the FDA
Sandoz upgraded to Buy from Hold at Jefferies
Jefferies analyst James Vane-Tempest upgraded Sandoz (SDZNY) to Buy from Hold with a price target of CHF 75, up from CHF 51.40. The firm believes the shares at current levels
Sandoz price target raised to CHF 63 from CHF 60 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Sandoz (SDZNY) to CHF 63 from CHF 60 and keeps a Buy rating on the shares.
Sandoz price target raised to CHF 55 from CHF 49 at Berenberg
Berenberg raised the firm’s price target on Sandoz (SDZNY) to CHF 55 from CHF 49 and keeps a Hold rating on the shares.
Sandoz price target raised to CHF 63 from CHF 60 at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on Sandoz (SDZNY) to CHF 63 from CHF 60 and keeps a Buy rating on the shares. Published first on
Sandoz price target raised to CHF 70 from CHF 55 at Barclays
Barclays raised the firm’s price target on Sandoz (SDZNY) to CHF 70 from CHF 55 and keeps an Overweight rating on the shares.
Sandoz initiated with a Neutral at Oddo BHF
Oddo BHF analyst Martial Descoutures initiated coverage of Sandoz (SDZNY) with a Neutral rating and CHF 57 price target
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in November Agreement includes approximately US$ 350 m in cash for Just ...
Sandoz price target raised to CHF 60 from CHF 55 at Deutsche Bank
Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on Sandoz (SDZNY) to CHF 60 from CHF 55 and keeps a Buy rating on the shares. Published first on
Sandoz CEO expects Ozempic biosimilars to enter Canadian market in Q1, Q2
Generic drug giant Sandoz expects unbranded versions of Novo Nordisk's popular diabetes drug Ozempic to launch in Canada by the second quarter next year after a key patent expires, its CEO said on Wed...
EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A
TAIPEI , Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (...
Sandoz price target raised to CHF 60 from CHF 55 at JPMorgan
JPMorgan raised the firm’s price target on Sandoz (SDZNY) to CHF 60 from CHF 55 and keeps an Overweight rating on the shares.
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerati...